| 1. |
- Abdo, A. A., et al.
(författare)
-
OBSERVATIONS OF MILKY WAY DWARF SPHEROIDAL GALAXIES WITH THE FERMI-LARGE AREA TELESCOPE DETECTOR AND CONSTRAINTS ON DARK MATTER MODELS
- 2010
-
Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 712:1, s. 147-158
-
Tidskriftsartikel (refereegranskat)abstract
- We report on the observations of 14 dwarf spheroidal galaxies (dSphs) with the Fermi Gamma-Ray Space Telescope taken during the first 11 months of survey mode operations. The Fermi telescope, which is conducting an all-sky gamma-ray survey in the 20 MeV to > 300 GeV energy range, provides a new opportunity to test particle dark matter models through the expected gamma-ray emission produced by pair annihilation of weakly interacting massive particles (WIMPs). Local Group dSphs, the largest galactic substructures predicted by the cold dark matter scenario, are attractive targets for such indirect searches for dark matter because they are nearby and among the most extreme dark matter dominated environments. No significant gamma-ray emission was detected above 100 MeV from the candidate dwarf galaxies. We determine upper limits to the gamma-ray flux assuming both power-law spectra and representative spectra from WIMP annihilation. The resulting integral flux above 100 MeV is constrained to be at a level below around 10(-9) photons cm(-2) s(-1). Using recent stellar kinematic data, the gamma-ray flux limits are combined with improved determinations of the dark matter density profile in eight of the 14 candidate dwarfs to place limits on the pair-annihilation cross section of WIMPs in several widely studied extensions of the standard model, including its supersymmetric extension and other models that received recent attention. With the present data, we are able to rule out large parts of the parameter space where the thermal relic density is below the observed cosmological dark matter density and WIMPs (neutralinos here) are dominantly produced non-thermally, e. g., in models where supersymmetry breaking occurs via anomaly mediation. The gamma-ray limits presented here also constrain some WIMP models proposed to explain the Fermi and PAMELA e(+)e(-) data, including low-mass wino-like neutralinos and models with TeV masses pair annihilating into muon-antimuon pairs.
|
|
| 2. |
- Steele, A., et al.
(författare)
-
A Reduced Organic Carbon Component in Martian Basalts
- 2012
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 337:6091, s. 212-215
-
Tidskriftsartikel (refereegranskat)abstract
- The source and nature of carbon on Mars have been a subject of intense speculation. We report the results of confocal Raman imaging spectroscopy on 11 martian meteorites, spanning about 4.2 billion years of martian history. Ten of the meteorites contain abiotic macromolecular carbon (MMC) phases detected in association with small oxide grains included within high-temperature minerals. Polycyclic aromatic hydrocarbons were detected along with MMC phases in Dar al Gani 476. The association of organic carbon within magmatic minerals indicates that martian magmas favored precipitation of reduced carbon species during crystallization. The ubiquitous distribution of abiotic organic carbon in martian igneous rocks is important for understanding the martian carbon cycle and has implications for future missions to detect possible past martian life.
|
|
| 3. |
|
|
| 4. |
- Do, T., et al.
(författare)
-
THREE-DIMENSIONAL STELLAR KINEMATICS AT THE GALACTIC CENTER : MEASURING THE NUCLEAR STAR CLUSTER SPATIAL DENSITY PROFILE, BLACK HOLE MASS, AND DISTANCE
- 2013
-
Ingår i: The Astrophysical Journal Letters. - 2041-8205. ; 779:1, s. L6-
-
Tidskriftsartikel (refereegranskat)abstract
- We present three-dimensional (3D) kinematic observations of stars within the central 0.5 pc of the Milky Way (MW) nuclear star cluster (NSC) using adaptive optics imaging and spectroscopy from the Keck telescopes. Recent observations have shown that the cluster has a shallower surface density profile than expected for a dynamically relaxed cusp, leading to important implications for its formation and evolution. However, the true 3D profile of the cluster is unknown due to the difficulty in de-projecting the stellar number counts. Here, we use spherical Jeans modeling of individual proper motions and radial velocities to constrain, for the first time, the de-projected spatial density profile, cluster velocity anisotropy, black hole mass (MBH), and distance to the Galactic center (R-0) simultaneously. We find that the inner stellar density profile of the late-type stars,(r). r-, have a power lawslope. = 0.05+ 0.29 -0.60, much more shallow than the frequently assumed Bahcall-Wolf slope of. = 7/4. The measured slope will significantly affect dynamical predictions involving the cluster, such as the dynamical friction time scale. The cluster core must be larger than 0.5 pc, which disfavors some scenarios for its origin. Our measurement of MBH = 5.76+ 1.76 -1.26 x 106M similar to and R0 = 8.92+ 0.58 -0.55 kpc is consistent with that derived from stellar orbits within 1 + of Sgr A*. When combined with the orbit of S0-2, the uncertainty on R0 is reduced by 30% (8.46+ 0.42 -0.38 kpc). We suggest that the MW NSC can be used in the future in combination with stellar orbits to significantly improve constraints on R0.
|
|
| 5. |
- Hassler, Donald M., et al.
(författare)
-
Mars’ surface radiation environment measured with the Mars Science Laboratory’s Curiosity Rover
- 2014
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 343:6169
-
Tidskriftsartikel (refereegranskat)abstract
- The Radiation Assessment Detector (RAD) on the Mars Science Laboratory’s Curiosity rover began making detailed measurements of the cosmic ray and energetic particle radiation environment on the surface of Mars on 7 August 2012. We report and discuss measurements of the absorbed dose and dose equivalent from galactic cosmic rays and solar energetic particles on the martian surface for ~300 days of observations during the current solar maximum. These measurements provide insight into the radiation hazards associated with a human mission to the surface of Mars and provide an anchor point with which to model the subsurface radiation environment, with implications for microbial survival times of any possible extant or past life, as well as for the preservation of potential organic biosignatures of the ancient martian environment.
|
|
| 6. |
- Rafkin, Scot C.R., et al.
(författare)
-
Diurnal variations of energetic particle radiation at the surface of Mars as observed by the Mars Science Laboratory Radiation Assessment Detector
- 2014
-
Ingår i: Journal of Geophysical Research - Planets. - 2169-9097 .- 2169-9100. ; 119:6, s. 1345-1358
-
Tidskriftsartikel (refereegranskat)abstract
- The Radiation Assessment Detector onboard the Mars Science Laboratory rover Curiosity is detecting the energetic particle radiation at the surface of Mars. Data collected over the first 350 Martian days of the nominal surface mission show a pronounced diurnal cycle in both the total dose rate and the neutral particle count rate. The diurnal variations detected by the Radiation Assessment Detector were neither anticipated nor previously considered in the literature. These cyclic variations in dose rate and count rate are shown to be the result of changes in atmospheric column mass driven by the atmospheric thermal tide that is characterized through pressure measurements obtained by the Rover Environmental Monitoring Station, also onboard the rover. In addition to bulk changes in the radiation environment, changes in atmospheric shielding forced by the thermal tide are shown to disproportionately affect heavy ions compared to H and He nuclei.
|
|
| 7. |
- Rinne, Juha O, et al.
(författare)
-
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
- 2010
-
Ingår i: Lancet neurology. - 1474-4465. ; 9:4, s. 363-72
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer's disease. METHODS: Patients with mild-to-moderate Alzheimer's disease were randomly assigned to receive intravenous bapineuzumab or placebo in a ratio of seven to three in three ascending dose groups (0.5, 1.0, or 2.0 mg/kg). Each dose group was enrolled after safety review of the previous group. Randomisation was by interactive voice response system; masking was achieved with numbered kit allocation. Patients, investigators, study site personnel, sponsor staff, and carers were masked to treatment. Patients received up to six infusions, 13 weeks apart, and had (11)C-PiB PET scans at baseline and at weeks 20, 45, and 78. The primary outcome was the difference between the pooled bapineuzumab group and the pooled placebo group in mean change from screening to week 78 in (11)C-PiB cortical to cerebellar retention ratio averaged across six cortical regions of interest. Analysis was by modified intention to treat. This study is registered with EudraCT, number 2004-004120-12; ISRCTN17517446. FINDINGS: 28 patients were assigned to bapineuzumab (n=20) or placebo (n=8). 19 patients in the bapineuzumab group and seven in the placebo group were included in the modified intention-to-treat analysis. Estimated mean (11)C-PiB retention ratio change from baseline to week 78 was -0.09 (95% CI -0.16 to -0.02; p=0.014) in the bapineuzumab group and 0.15 (95% CI 0.02 to 0.28; p=0.022) in the placebo group. Estimated mean difference in (11)C-PiB retention ratio change from baseline to week 78 between the bapineuzumab group and the placebo group was -0.24 (95% CI -0.39 to -0.09; p=0.003). Differences between the bapineuzumab group and the placebo group in the individual regions of interest were similar to the overall mean difference. Adverse events were typically mild to moderate in severity and transient. Two patients in the 2.0 mg/kg bapineuzumab group had transient cerebral vasogenic oedema. INTERPRETATION: Treatment with bapineuzumab for 78 weeks reduced cortical (11)C-PiB retention compared with both baseline and placebo. (11)C-PiB PET seems to be useful in assessing the effects of potential Alzheimer's disease treatments on cortical fibrillar amyloid-beta load in vivo. FUNDING: Elan Pharmaceuticals and Wyeth Research.
|
|
| 8. |
- Bullock, A, et al.
(författare)
-
International standards for programmes of training in intensive care medicine in Europe
- 2011
-
Ingår i: Intensive Care Medicine. - : Springer Science and Business Media LLC. - 0342-4642 .- 1432-1238. ; 37:3, s. 385-393
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE:To develop internationally harmonised standards for programmes of training in intensive care medicine (ICM).METHODS:Standards were developed by using consensus techniques. A nine-member nominal group of European intensive care experts developed a preliminary set of standards. These were revised and refined through a modified Delphi process involving 28 European national coordinators representing national training organisations using a combination of moderated discussion meetings, email, and a Web-based tool for determining the level of agreement with each proposed standard, and whether the standard could be achieved in the respondent's country.RESULTS:The nominal group developed an initial set of 52 possible standards which underwent four iterations to achieve maximal consensus. All national coordinators approved a final set of 29 standards in four domains: training centres, training programmes, selection of trainees, and trainers' profiles. Only three standards were considered immediately achievable by all countries, demonstrating a willingness to aspire to quality rather than merely setting a minimum level. Nine proposed standards which did not achieve full consensus were identified as potential candidates for future review.CONCLUSIONS:This preliminary set of clearly defined and agreed standards provides a transparent framework for assuring the quality of training programmes, and a foundation for international harmonisation and quality improvement of training in ICM.
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- O'Brien, John T, et al.
(författare)
-
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
- 2011
-
Ingår i: Journal of psychopharmacology (Oxford, England). - : SAGE Publications. - 1461-7285 .- 0269-8811. ; 25:8, s. 997-1019
-
Forskningsöversikt (refereegranskat)abstract
- The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A to D, with A having the strongest evidence base (from randomized controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and brain imaging can improve diagnostic accuracy (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for mild to moderate Alzheimer's disease (A) and memantine for moderate to severe Alzheimer's disease (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (Parkinson's disease dementia and dementia with Lewy bodies (DLB)), especially for neuropsychiatric symptoms (A). Cholinesterase inhibitors and memantine can produce cognitive improvements in DLB (A). There is no clear evidence that any intervention can prevent or delay the onset of dementia. Although the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition are in progress. Although results of pivotal studies are awaited, results to date have been equivocal and no disease-modifying agents are either licensed or can be currently recommended for clinical use.
|
|
